Oral Pinealon and Vesugen in older men: four-arm randomized comparison
Randomized study in people · 2010
- What was studied
- 170 men aged 60–74. Pinealon 43, Vesugen 45, both 42, Decamevit multivitamin control 40.
- Main finding
- After 30 days, working-memory scores were 17.4 with Pinealon, 17.8 with Vesugen and 17.5 with both, versus 12.4 with multivitamins. The combination had the largest change on the composite severity index. At five-month follow-up, the figure marks a baseline difference only for that index in the combination arm.
Reported findings and study design
Block-randomized comparison in 170 men aged 60–74. Four parallel arms, a 30-day course, and a follow-up five months after the course ended.
Population or model 170 men aged 60–74. Pinealon 43, Vesugen 45, both 42, Decamevit multivitamin control 40.
Dose, route and schedule
One capsule of the assigned peptide twice daily for 30 days. The combination group received one capsule of each twice daily. The reference group received Decamevit, an active multivitamin.
Protocol source ↗ · 2010 author-abstract scan, Tables 1–4 and Fig. 2, and corresponding 2018 monograph, §6.2, Tables 6.16–6.18
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Working-memory score · after course | 17.4 Pinealon, 17.8 Vesugen, 17.5 combined, 12.4 control | Baseline scores 9.8, 9.4, 8.4 and 9.1, respectively. · All peptide arms marked p < 0.05 versus the multivitamin control. |
| Short-term visual memory for numbers · after course | 3.5 Pinealon, 2.8 Vesugen, 3.7 combined, 2.0 control | Baseline scores 1.9, 1.9, 1.9 and 2.1. · Pinealon and combination marked p < 0.05 versus control. |
| Composite psychosomatic severity · after course | 69.45 Pinealon, 79.42 Vesugen, 46.20 combined, 80.25 control | Study-specific composite. Lower values indicate lower severity. · Pinealon and combination marked p < 0.05 versus baseline and comparison groups in Table 6.16. |
| Long-term memory score · after course | 18.1 Pinealon, 17.0 Vesugen, 21.6 combined, 15.5 control | Baseline scores differed across groups. · The combination is the only arm marked significant versus control. |
| State anxiety · after course | 11.8 Pinealon, 13.4 Vesugen, 8.7 combined, 18.4 control | Baseline scores 17.5 in each peptide arm and 19.1 with the multivitamin. See the author abstract, Table 2. · All three peptide arms marked p < 0.05 versus baseline and control. The combination was also marked lower than either single-peptide arm. |
| Five-month follow-up · author abstract Figure 2 | Only the combination’s severity-index bar carries a significance marker | The plotted bar is about 4% on the figure’s change scale. Memory and the other plotted measures carry no significance markers at this visit. Follow-up sample sizes are unspecified. · The marker denotes p < 0.05 versus the group’s own baseline. |
Tables 6.16 and 6.18 · selected baseline and post-course results
| Measure | Pinealon (43) | Vesugen (45) | Combination (42) | Decamevit (40) |
|---|---|---|---|---|
| Working memory | 9.8 ± 1.3 → 17.4 ± 0.9 | 9.4 ± 1.5 → 17.8 ± 1.3 | 8.4 ± 1.6 → 17.5 ± 0.5 | 9.1 ± 1.7 → 12.4 ± 1.8 |
| Short-term visual memory | 1.9 ± 0.5 → 3.5 ± 0.2 | 1.9 ± 0.4 → 2.8 ± 1.2 | 1.9 ± 0.1 → 3.7 ± 0.3 | 2.1 ± 0.3 → 2.0 ± 0.7 |
| Long-term memory | 15.4 ± 1.3 → 18.1 ± 1.3 | 16.4 ± 0.8 → 17.0 ± 1.4 | 12.4 ± 1.3 → 21.6 ± 1.7 | 14.4 ± 1.4 → 15.5 ± 1.9 |
| Severity index | 80.64 ± 5.32 → 69.45 ± 3.16 | 82.31 ± 3.47 → 79.42 ± 4.23 | 80.35 ± 4.06 → 46.20 ± 3.44 | 81.76 ± 2.75 → 80.25 ± 3.40 |
| Recovery index | 19.65 ± 3.45 → 39.1 ± 2.19 | 18.02 ± 3.42 → 24.42 ± 5.31 | 19.12 ± 2.05 → 56.14 ± 3.43 | 19.45 ± 3.16 → 20.81 ± 2.21 |
Scores and ± terms as printed in the 2018 monograph. The short-term visual-memory narrative gives a different ± term for the Vesugen endpoint. Numbers in the headings are original group assignments.
The study reports similar working-memory scores in three peptide arms and a larger composite change with the combination. The active multivitamin control, unclear masking and multiple outcomes limit interpretation.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Block randomization is reported. Allocation concealment, matching or masking, follow-up group counts and systematic harms collection are unclear.
- The authors called Decamevit a placebo. It is an active multivitamin. Multiple tests and a study-specific composite limit inference. The study did not assess dementia prevention.
- The dissertation and monograph report the same four arm sizes and results. The conference citations require the original proceedings to establish participant overlap.
Related publications may describe some of the same participants or experiments.
Source details
Dissertation author abstract
2010 author-abstract scan, Tables 1–4 and Fig. 2, and corresponding 2018 monograph, §6.2, Tables 6.16–6.18
Sources checked
Added to the library
Citation
A. V. Dudkov. Oral Pinealon and Vesugen in older men: four-arm randomized comparison St Petersburg, 2010 dissertation author abstract. Results also reproduced in Khavinson et al., Nauka, 2018, §6.2.
Related compounds
Pinealon
A synthetic tripeptide, Glu–Asp–Arg (EDR). Researchers have examined its effects in neuronal aging models and measured functional outcomes in human performance studies.
Vesugen
A synthetic three-amino-acid peptide (Lys–Glu–Asp, or KED) studied in vascular and cell-aging research.